In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients.

Kenichi A TanakaReney HendersonKiruphagaran ThangarajuYoshihisa MoritaMichael A MazzeffiErik StraussUpendra KatneniPaul W Buehler

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)

FVIII inhibitors extensively prolong ACTs in heparinized whole blood, and clinical levels of emicizumab partially reverse ACT values. Protamine titration should be considered for optimal heparin monitoring in emicizumab-treated patients with FVIII inhibitors.

Keyphrases

multidrug resistant
venous thromboembolism
left ventricular
growth factor
atrial fibrillation